J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (21)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Doan, T.
Right arrow Articles by Massarotti, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Doan, T.
Right arrow Articles by Massarotti, E.

THERAPEUTIC REVIEW

Rheumatoid Arthritis: An Overview of New and Emerging Therapies

Tanya Doan, MD, CM and Elena Massarotti, MD, FACP

From the Tufts-New England Medical Center, Boston, Massachusetts.

Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic autoimmune disorder characterized by symmetric inflammation of synovial joints leading to progressive erosion of cartilage and bone. The aim of treatment is to mitigate joint destruction, preserve function, and prevent disability. The American College of Rheumatology guidelines for the treatment of RA recommend that newly diagnosed patients with RA begin treatment with disease-modifying antirheumatic drugs (DMARDs) within 3 months of diagnosis. Methotrexate remains the most commonly prescribed DMARD and is the standard by which recent new and emerging therapies are measured. Increasing knowledge regarding the immunologic basis of RA and advances in biotechnology have resulted in new, targeted biological therapies against proinflammatory cytokines that have dramatically changed the treatment paradigm and outcomes of patients with RA. This article reviews the pharmacological rationale underlying RA therapy, with a focus on currently available biological therapies and new therapies in development.

Key Words: Rheumatoid arthritis • biological therapies • cytokines

Address for reprints: Elena Massarotti, MD, 750 Washington Street, NEMC 599, Boston, MA 02111.




This article has been cited by other articles:


Home page
 J Biomol ScreenHome page
Y. Ibold, S. Frauenschuh, C. Kaps, M. Sittinger, J. Ringe, and P. M. Goetz
Development of a High-Throughput Screening Assay Based on the 3-Dimensional Pannus Model for Rheumatoid Arthritis
J Biomol Screen, October 1, 2007; 12(7): 956 - 965.
[Abstract] [PDF]

Home page
 J. Neurosci.Home page
C. D. Conrad, K. J. McLaughlin, J. S. Harman, C. Foltz, L. Wieczorek, E. Lightner, and R. L. Wright
Chronic Glucocorticoids Increase Hippocampal Vulnerability to Neurotoxicity under Conditions That Produce CA3 Dendritic Retraction But Fail to Impair Spatial Recognition Memory
J. Neurosci., August 1, 2007; 27(31): 8278 - 8285.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Y. Nakai, K. Inoue, N. Abe, M. Hatakeyama, K.-y. Ohta, M. Otagiri, Y. Hayashi, and H. Yuasa
Functional Characterization of Human Proton-Coupled Folate Transporter/Heme Carrier Protein 1 Heterologously Expressed in Mammalian Cells as a Folate Transporter
J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 469 - 476.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S. P Bruce and E. G Boyce
Update on Abatacept: A Selective Costimulation Modulator for Rheumatoid Arthritis
Ann. Pharmacother., July 1, 2007; 41(7): 1153 - 1162.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American College of Clinical Pharmacology